Atezolizumab Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
JAMA Oncol 2022 Dec 15;[EPub Ahead of Print], M Provencio, AL Ortega, J Coves-Sarto, V Calvo, R Marsé-Fabregat, M Dómine, M Guirado, E Carcereny, N Fernández, R Álvarez, R Blanco, L León-Mateos, JM Sánchez-Torres, IG Sullivan, M Cobo, A Sánchez-Hernández, B Massuti, B Sierra-Rodero, C Mártinez-Toledo, R Serna-Blasco, A Romero, A Cruz-BermúdezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.